Researchers produced a panel of platform cell lines illustrating how glycoform selection can be made experimentally visible earlier in biologics development.
- Achieving Annex 1 Compliance In Sterile Manufacturing, Part 1: Common Compliance Failures
- Hormuz Deal Brings Cautious Relief To Pharma Packaging Supply Chains
- Is Your AI Model Trustworthy And Credible In GMP Processes?
- Midyear Pulse Check: What's Shaping Biopharma In 2026?
- May 2026 — CDMO Opportunities And Threats Report
- FDA's Guidance On Cell And Gene CMC Codifies Flexibility
- Where Does 3D-Printed Single-Use Tech Fit In The Development Pipeline?
EDITOR'S DESK
-
Can A Biotech Create A CDMO Market?
Can a biotech create a CDMO market? GeoVax, an infectious disease/oncology biotech, may have just done so. David Dodd, CEO, believes we should all concentrate more on whether the outsourcing model can align with evolving technology platforms. Both sponsors and CDMOs may need to change things up.
Bioprocess Online caught up with Tiffany D. Rau, Ph.D., CMC consultant and adjunct professor of biochemistry and cell biology at the University College Cork in Ireland, at Oxford Global's 2026 NextGen Biomed conference.
Coordinating unit operations can help reduce costs and mitigate challenges in process development. Check out these key takeaways from the Bioprocess Online Live event “Optimizing Process Development Through Upstream and Downstream Integration.”
It sets off a real tension – ideological, economic, even personal. But what would happen if the U.S. government cut direct financial support for “biotechnology research,” leaving it entirely to investors, private and public markets, and bigger pharma? "Our industry’s mind-meld says with no government largesse our biotech industry collapses," writes Chief Editor Louis Garguilo. It's an "outlandish hypothetical," but he asks for a few minutes to go through this. And he has help in making his case.
“I assist C-suite executives to transfer quality from a painful cost center to a competitive asset." It's the type of bold statement that draws one's attention. Chief Editor Louis Garguilo asked David Grote on what his assertion means materially – and how that’s applied to working with CDMOs. Here's their discussion that focuses on a transformation that moves executives from regarding quality as ‘overhead’ to recognizing quality as “an operational element for business advantage.”
GUEST COLUMNISTS
-
Achieving Annex 1 Compliance In Sterile Manufacturing, Part 1: Common Compliance Failures
A persistent gap remains between what Annex 1 requires and what facilities can demonstrate. Let's take a closer look at four common compliance failures.
-
Hormuz Deal Brings Cautious Relief To Pharma Packaging Supply Chains
Restrictions and fear on the Hormuz Strait have fractured supply chains, especially for primary materials used in pharmaceutical packaging.
-
Is Your AI Model Trustworthy And Credible In GMP Processes?
Credibility and trustworthiness in AI models are related but distinct attributes. If you're using them in GMP manufacturing, you should understand the difference.
-
May 2026 — CDMO Opportunities And Threats Report
Each month, Outsourced Pharma works in conjunction with PharmSource, part of GlobalData, to present its “Contract Manufacturing: Opportunities and Threats (CMOT) Report” to our readers. The report identifies CDMOs that might be impacted by key events affecting their clients, including company acquisitions, product acquisitions and licenses, product approvals, late clinical product terminations, and FDA rejections.
-
FDA's Guidance On Cell And Gene CMC Codifies Flexibility
The final guidance articulates common practices around validation, stability data, and reserve samples that, up until now, had been applied on a case-by-case basis.
-
Where Does 3D-Printed Single-Use Tech Fit In The Development Pipeline?
Additive manufacturing in early-phase process development is growing more common, but the practice comes with important considerations.
-
Use Of AI In FDA Inspection Activities: Strategies For Effective Preparation
Are you ready? FDA has begun to implement the use of artificial intelligence in its operations, particularly during inspection activities.
-
A Comparison Of 6 Analytical Validation Guidelines Using Data Envelopment Analysis
This is the first published application of data envelopment analysis to six major pharmaceutical analytical validation guidelines, including ICH Q2(R2), USP, ChP, and Brazil's ANVISA.
BIOPROCESSING WHITE PAPERS
-
Unlocking ROI And Capacity In Monoclonal Antibody Manufacturing
Perfusion-based upstream production offers up to 24% lower cost and significantly higher productivity than fed-batch, enabling faster timelines, better facility utilization, and improved quality.
-
Seasonal Vaccine Manufacturing: 3 Areas To Evaluate When Selecting A Partner10/16/2024
Experienced outsourcing partners will have the right facility and technical capabilities, a culture of speed and execution, and shared expectations and commitment to continuous improvement.
-
Scaling With The Client In Mind: A Customer-Centric Approach To Project Scale-Up1/22/2026
In today’s fast-moving biopharma landscape, scaling from clinic to commercial takes more than expertise. See how collaboration can transform scale-up and drive confident progress
-
Cell Line Development For Bispecific Antibodies8/18/2025
See how the recently described cell line development paradigm shift, enabled by the Leap-In transposon platform, can extend to the development of bispecific monoclonal antibody-producing cell substrates.
-
Enhancing Host Cell DNA Testing With Digital PCR6/24/2026
Residual host cell DNA testing is evolving with digital PCR. Discover how streamlined methods improve accuracy, minimize manual steps, and support efficient biopharmaceutical manufacturing processes.
-
Advancing Drug Safety And Improving R&D Productivity With The Liver-Chip S112/10/2024
Explore how the Emulate Liver-Chip S1 revolutionizes predictive toxicology by mimicking human liver biology, achieving superior sensitivity and specificity.
BIOPROCESSING APP NOTES & CASE STUDIES
- Single-Use Assembly Capabilities To Keep Pace With Biopharma Dynamics
- A Dilute-And-Shoot Method For Monitoring mAb PQAs From Spent Media
- Automating Mass Spectrometry Analysis To Accelerate Oligonucleotide Drug Development
- Ensuring Product Safety And Purity With Mycoplasma And Sterility Testing
- Ensuring Viral Safety Through Multiplexed Adventitious Virus Detection
- Midyear Pulse Check: What's Shaping Biopharma In 2026?
- Reflecting On Continued Turbulence At The FDA
- Insufficient Vendor Data Is Hamstringing Single-Use Adoption
- On The Ground At NextGen Biomed 2026
- Integrate Upstream/Downstream To Reduce Development Risks And Costs
- Taking The First Steps Towards Digitalizing Biopharma Development
- Bioprocess Online's 2025 Editorial Reflections
BIOPROCESS ONLINE CONTENT COLLECTIONS
This collection of articles digs into the industry’s growing focus on knowledge management as an indispensable facet of biomanufacturing and pharmaceutical development, exploring how it plays into risk management, quality, vendor relationships, and supply chain resilience.
More Content CollectionsFEATURED PRODUCTS AND SERVICES
ON-DEMAND WEBINARS
- Building Scalable Non-Viral Gene-Edited Cell Therapy Processes
- Automating Cell Therapy Manufacturing Without Redesigning Workflows
- How Intensified Upstream Processing Improves Scale-Up And Tech Transfer
- Generate Stable High-Producing Clones In 14 Weeks
- Creative Chromatography Solutions For Complex Small Molecules
INDUSTRY NEWS
NEWSLETTER ARCHIVE
- 06.27.26 -- Focusing On The Big Picture And The Factors Shaping Biopharma In 2026
- 06.26.26 -- STREAM Edition: Evaluating And Prioritizing CQAs In Viral Vector Production
- 06.26.26 -- What To Do About Process Drift In Your Biosimilar's Reference Product
- 06.25.26 -- Fixing The Fragmentation In Outsourced Pharma
- 06.25.26 -- May 2026 — CDMO Opportunities And Threats Report